Want to see KNSA full AI Analyst Report?
KNSA Stock Chart & Stats
$62.84
$1.29(2.05%)
At close: 4:00 PM EDT
$62.84
$1.29(2.05%)
Day’s Range― - ―
52-Week Range$32.89 - $82.94
Previous CloseN/A
Volume57.84K
Average Volume (3M)854.87K
Market Cap
$6.18B
Enterprise Value$4.82K
Total Cash (Recent Filing)$525.93M
Total Debt (Recent Filing)$8.90M
Price to Earnings (P/E)74.0
Beta0.45
Next Earnings
Nov 03, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding48,289,272
10 Day Avg. Volume498,082
30 Day Avg. Volume854,867
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)5.39
Price to Sales (P/S)4.52
P/FCF Ratio120.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$96.57Price Target Upside53.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.39
Revenue Forecast (FY)$993.64M
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthKiniksa's minimal leverage and large equity base provide durable financial flexibility to fund commercialization, clinical programs, and potential M&A without reliance on dilutive equity or expensive debt. This permanently lowers solvency risk and supports multi‑year investment in growth initiatives.
Cash GenerationConsistent, substantial operating and free cash flow plus a half‑billion cash balance underpin self‑funding of R&D and commercialization. Strong FCF supports durable reinvestment in pipeline and sales capability, reducing dependency on external financing over the next several years.
Commercial Momentum & PipelineRapid ARCALYST revenue growth, expanding prescriber adoption and higher penetration show a scalable commercial model producing repeatable revenues. Advancement of KPL‑387 to Phase III diversifies long‑term growth potential beyond the current asset, strengthening multi‑year revenue visibility.
Bears Say
Rising Operating ExpensesSustained increases in COGS, R&D and commercialization spend can compress operating leverage and limit margin expansion as the company scales. If expense growth outpaces revenue gains, durable profitability and incremental free cash flow could be constrained over the medium term.
Gross-to-Net UncertaintyVolatile gross‑to‑net dynamics and lack of forward guidance create uncertainty around realized net revenue and margins. Persistent shifts in co‑pay support or payer reimbursements could structurally reduce net sales and complicate multi‑period planning for commercial investment and profitability.
Earnings/Cashflow VolatilityLarge year‑to‑year swings in operating cash flow and prior operating losses signal working‑capital and timing volatility. This reduces confidence in earnings durability and makes multi‑period cash forecasting for R&D and commercial scale‑up less reliable, raising execution risk.
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals Ltd. Class A’s price range in the past 12 months?
Kiniksa Pharmaceuticals Ltd. Class A lowest stock price was $32.89 and its highest was $82.94 in the past 12 months.
What is Kiniksa Pharmaceuticals Ltd. Class A’s market cap?
Kiniksa Pharmaceuticals Ltd. Class A’s market cap is $6.18B.
When is Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date?
Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date is Nov 03, 2026 which is in 76 days.
How were Kiniksa Pharmaceuticals Ltd. Class A’s earnings last quarter?
Kiniksa Pharmaceuticals Ltd. Class A released its earnings results on Jul 28, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of $0.299 by $0.001.
Is Kiniksa Pharmaceuticals Ltd. Class A overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals Ltd. Class A’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals Ltd. Class A pay dividends?
Kiniksa Pharmaceuticals Ltd. Class A does not currently pay dividends.
What is Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate?
Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate is 0.37.
How many shares outstanding does Kiniksa Pharmaceuticals Ltd. Class A have?
Kiniksa Pharmaceuticals Ltd. Class A has 48,289,272 shares outstanding.
What happened to Kiniksa Pharmaceuticals Ltd. Class A’s price movement after its last earnings report?
Kiniksa Pharmaceuticals Ltd. Class A reported an EPS of $0.3 in its last earnings report, beating expectations of $0.299. Following the earnings report the stock price went up 25.033%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals Ltd. Class A?
Currently, no hedge funds are holding shares in KNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.57 (53.68% Upside)
$96.57 (53.68% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 60%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $299.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.54%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals Ltd. Class A
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
KNSA Company Deck
KNSA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution for ARCALYST with substantial quarter-over-quarter and year-over-year revenue gains, expanded prescriber adoption, improved collaboration profit, a robust cash position, and positive Phase II data supporting a monthly KPL-387 regimen and initiation of the pivotal Phase III trial. Challenges include rising operating expenses, limited disclosure on some clinical follow-up details, remaining underdiagnosis in the market that requires continued education, and uncertainty around gross-to-net trends and future commercial resource expansion. On balance, the positive commercial and clinical milestones materially outweigh the noted operational and disclosure limitations.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$96.57
▲(53.68% Upside)
Technical Analysis
Corcept Therapeutics
―
SCYNEXIS
―
Liquidia Technologies
―
Biofrontera
―
Nasus Pharma Ltd.
―
Ownership Overview
8.74% Insiders
23.16% Mutual Funds
32.58% Other Institutional Investors
21.37% Public Companies and
Individual Investors